Recent evidence indicates that, in addition to the involvement of cholinergic and other neurotransmitter systems, various neuropeptides that occur in cortical and subcortical brain regions have a role in cognitive behavior. This evidence results largely from behavioral studies in rodents and other animals, following peptide administration and only in a very few cases from similar studies in human subjects. Several neuropeptides studied appear to enhance or produce changes conducive to improvement in cognitive performance and these include vasopressin, corticotrophin-releasing hormone (CRH), somatostatin, substance P, neuropeptide Y, and thyrotrophin-releasing hormone (TRH), while one peptide, galanin, has been reported to inhibit cognitive processes. Of those neuropeptides that improve performance, only TRH has been shown recently to attenuate the memory impairment of human subjects and Alzheimer patients treated with an anticholinergic drug, and this review describes a series of complimentary studies in adult and aged rodents that contribute to our understanding of the possible mechanisms involved in the role of TRH in cognition.

Aging↗

PubMedDate not supplied

Proton penetration and control in nonhomogeneous phantoms.

Accurate bolus is needed for extension of Bragg-peak therapy. Proton beam-stopping profiles in a lucite-styrofoam-tissue phantom and in a Rando phantom were recorded photographically. Air volumes caused the largest distortions. Lucite bolus was cut to achieve desired beam-stopping profiles. Verification of bolus effect in situ will be important to control beam penetration within 5 mm.

Models, Structural↗

PubMedDate not supplied

Experimental tests of proton beam localization.

The depth of penetration of heavy charged-particle therapy beams is sensitive to the density of tissues traversed. Maximum depth of dose contours will vary appreciably as the beam passes through bone, muscle, lung, and air or gas. Calculations suggest that beam activation of the short-lived positron-emitting isotope 15O in vivo will permit localization of proton therapy beams with resonable detected-event density and dose. Preliminary tests of this method indicate that the beam can be located at depth with a typical dose of 15 rad, using a large field-of-view positron camera on-ling. This technique is also applicable to other heavy charged-particle beams, negative pions, and heavy ions.

Oxygen Radioisotopes↗

PubMedDate not supplied

Observations of the dynamics of ionic potassium-38 in brain.

Short time course potassium dynamics in brain were investigated in the cat. 38K (T1/2 = 7.6m) was prepared on the BNL 60" cyclotron by the 40Ar(p, 3n)38K reaction. Positron decay in brain was measured by the limited angle of view positron camera (LAPC). Radioactivity corrected for physical decay following intravenous bolus injection of 38K showed an initial peak followed by a washout phase with a subsequent monotonic increase. The slope of the washout phase was linearly related to PaCO2 and the subsequent monotonic increase paralleled the arterial concentration of the tracer. No significant changes in 38K radioactivity were determined following coma producing levels of phenobarbital or seizure producing doses of potassium penicillin as compared to control.

Animals↗

PubMedDate not supplied

The relation of proton activation of brain to cerebral blood flow.

The interaction of brain with high energy protons produces positron emitting nuclides. The present study examines the response of the decay events to oxygen-15 induced by such activation in brain to alterations of cerebral blood flow as measured by a limited angle planar positron camera. Decay events correlate directly to the cerebral blood flow. The interaction of brain with high energy protons appears to offer an alternative means for the delivery of a freely diffusible tracer into brain.

Animals↗